FTC Wades Into ‘Rebate Walls’ And Biosimilar Access With Remicade Investigation
Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.
You may also be interested in...
‘Rebate walls’ report heads to US Congress, but Democratic commissioners suggest FTC’s typical approach to curtailing such practices is too time consuming.
Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.
Legislation clears committee with no major changes. However, the number of Republicans opposing the bill due to concerns over price inflation rebates portend difficulties ahead for a floor vote.